Zynerba is conducting clinical studies of Zygel™ in a number of patients with a number of neuropsychiatric conditions in the United States, Australia, and New Zealand. Zygel is an experimental treatment. This means that it is not approved by government regulatory bodies, including the United States Food and Drug Administration (FDA) and other agencies and must be tested to see if it is an effective and safe treatment.
RECONNECT (Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome): Enrollment Ongoing
For more information regarding enrollment in RECONNECT, please see:
INSPIRE (Assessing the Impact of Zygel [Transdermal CBD Gel] on Pediatric Behavioral and Emotional Symptoms of 22q11.2 Deletion Syndrome). Enrollment ongoing
Read more about Zynerba’s clinical pipeline here.